Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Affinity and Avidity01:41

Affinity and Avidity

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renal transplantation outcomes in obese patients: a French cohort-based study.

BMC nephrology·2021
Same author

Utility of anaerobic bottles for the diagnosis of bloodstream infections.

BMC infectious diseases·2020
Same author

Intravenous Immunoglobulins in the Prevention of Rejection of a Second or Third Kidney Graft.

Transplantation proceedings·2018
Same author

The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Harnessing Scientific and Technological Advances to Improve Equity in Kidney Allocation Policies.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same journal

Nutritional monitoring in peritoneal dialysis: Biological and non-biological markers and dietary strategies

Nephrologie & therapeutique·2026
Same journal

Supporting patients and family members facing treatment choices in chronic kidney disease: What do professionals think of the decision aids used? - Professionals’ views on treatment decision support tools

Nephrologie & therapeutique·2026
Same journal

From Turing to ChatGPT: The origins and transformations of medical artificial intelligence

Nephrologie & therapeutique·2026
Same journal

Analysis of the predictive value of serum Cys-C and IL-6 levels for acute kidney injury in patients with acute respiratory distress syndrome.

Nephrologie & therapeutique·2026
Same journal

Navigating pain in chronic kidney disease: Overcoming inertia!

Nephrologie & therapeutique·2026
Same journal

Kidney health for all: caring for people, protecting the planet1.

Nephrologie & therapeutique·2026
See all related articles

Related Experiment Videos

[Antibody-mediated acute rejection].

C Lefaucheur1, D Nochy, D Glotz

  • 1Hôpital Saint-Louis, Avenue Claude Vellefaux, 75010 Paris, Paris, France. carmen.lefaucheur@sls.aphp.fr

Nephrologie & Therapeutique
|November 13, 2008
PubMed
Summary
This summary is machine-generated.

Preventing and treating antibody-mediated acute rejection in kidney transplants is crucial. Early antibody detection and targeted immunosuppression before and after transplantation improve outcomes for this severe complication.

Related Experiment Videos

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation Science

Background:

  • Antibody-mediated acute rejection (AMAR) is a significant and severe complication following kidney transplantation.
  • AMAR often presents with a poor prognosis and resistance to standard treatments, necessitating proactive and reactive management strategies.

Purpose of the Study:

  • To highlight the importance of pre-transplant antibody screening and post-transplant monitoring for managing AMAR.
  • To review current and effective treatment strategies for AMAR in kidney transplant recipients.

Main Methods:

  • Utilizing sensitive techniques like single antigen and ELISA for pre-transplant detection of donor-specific anti-HLA antibodies.
  • Implementing strict post-transplant monitoring of at-risk patients to adjust immunosuppression.
  • Employing antibody removal/blocking (IVIg, plasmapheresis) and B-cell depletion therapies (anti-CD20, thymoglobulins) for AMAR treatment.

Main Results:

  • Pre-transplant antibody quantification enables informed graft allocation and risk assessment.
  • Post-transplant monitoring allows for timely modification of immunosuppression strategies.
  • Therapies targeting antibodies or antibody-producing cells demonstrate efficacy in treating AMAR.

Conclusions:

  • Early identification and management of donor-specific anti-HLA antibodies are essential for successful kidney transplantation.
  • Persistence of donor-specific anti-HLA antibodies post-AMAR indicates a poor prognosis, underscoring the need for sustained suppression and follow-up.